quazepam

Trade name: doral

Small moleculeapproved

Approved

Dec 27, 1985

Quazepam is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Quazepam interact preferentially with the benzodiazepine-1 (BZ1) receptors. Most common adverse reactions (>1%): drowsiness, headache, fatigue, dizziness, dry mouth, dyspepsia. Downward of CAN depressant dose adjustment may be necessary due to additive effects. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1980s

Dec 27, 1985
Schering — Earliest FDA Approval
Dec 27, 1985
Galt Pharmaceuticals — NDA Secondary Org
Dec 27, 1985
Schering — NDA Organization

Indications

Approved for

Sleep Initiation and Maintenance Disorders (approved 1985)

Mechanism of action

GABA-A receptor; anion channelPOSITIVE ALLOSTERIC MODULATOR
GABA-A receptor; anion channel positive allosteric modulator
Benzodiazepine site

Approval history

approvedDec 27, 1985

Chemistry & pharmacology

Loading structure…

SMILES

FC1=CC=CC=C1C2=NCC(=S)N(CC(F)(F)F)C3=CC=C(Cl)C=C23

Mol. weight: 386.794 g/mol
Lipinski Ro5: 1 violation(s)
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral
Availability: Prescription Only

Oral

Yes

Parenteral

Topical

Black box warning

Sources

Also known as

7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1-(2,2,2-trifluoroethyl)-2h-1,4-benzodiazepine-2-thione
doral
doral
doral
doral
prosedar
quazepam
quazepam
quazepam
quazepam
quazepam
quazepam
quazepam
quazepam
quazepam
quazepamum
quazepamum
quazium
quiedorm
sch 16134
sch 16134
sch-16134
sch-16134
sch-16134
sch-16134
sch-16134

Organizations

Marketing (2)

Organization	Org type	Relationship	Date
Galt Pharmaceuticals	For profit	NDA2	Dec 27, 1985
Schering	For profit	NDA	Dec 27, 1985